OncoEthix

OncoEthix is a clinical stage biotechnology company developing innovative cancer drugs. OncoEthix SA was founded in 2007 to develop a portfolio of 3 to 5 promising new drugs for cancer treatment. The company intends to develop its compounds through clinical proof of concept and the identification of an expedited registration strategy, after which pharmaceutical partners will be sought to fund pivotal trials and handle commercialization.

In June 2012 OncoEthix in-licensed an anticancer compound from MTPC. OncoEthix product pipeline includes three first-in-class agents to novel cancer targets or with novel mode of action. Two of these agents are in clinical development.


Recent News

June 15, 2012
OncoEthix In-Licenses OTX015, an anticancer Bromodomain inhibitor from Mitsubishi Tanabe Pharma Corporation

 


Company Info
 
Country: Switzerland
Industry:    LS
Sector: biotechnology
Status: Unrealized
Vehicle: Endeavour II LP


Key persons
 Dr Esteban Cvitkovic; Dr Kay Noel; Dr. Patrice Herait; Bertrand Damour CEO


Company website
 www.oncoethix.com


Endeavour Vision Team
 
Olivier Valdenaire
Sven Lingjaerde
© Endeavour Vision SA 2006-2013 Terms & Conditions